<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04567095</url>
  </required_header>
  <id_info>
    <org_study_id>CMO-EPI-WH-0626</org_study_id>
    <nct_id>NCT04567095</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Awareness and Knowledge of the Fibristal Additional Risk Minimization Measures Among Patients in Canada</brief_title>
  <official_title>A Cross-sectional Study Among Patients in Canada to Assess Awareness and Knowledge of the Fibristal Patient Alert Card</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a non-interventional, cross-sectional survey study to evaluate the effectiveness of&#xD;
      the Additional Risk Minimization Measures for Fibristal among Patients in Canada.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Data will be collected via web-based data capture and paper surveys depending on patient&#xD;
      preference. The survey will be conducted in a single wave over 6 months. All data will be&#xD;
      maintained in compliance with local regulations.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    This study was cancelled before any data collection due to business reasons.&#xD;
  </why_stopped>
  <start_date type="Anticipated">October 31, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentages of patients with correct responses to the knowledge related questions based on the contents of the Fibristal Patient Alert Card.</measure>
    <time_frame>18 - 24 months</time_frame>
    <description>Correct responses to knowledge-related questions (i.e, potential of fibristal to cause liver injury, signs and symptoms of liver problems, and what to do in case of signs and symptoms of liver problems.)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentages of patients that recall recieving and using the Fibristal Patient Alert Card</measure>
    <time_frame>18 - 24 months</time_frame>
    <description>Receipt and use of the Fibristal Patient Alert Card,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients that recall their HCPs' ordering of required liver function tests in accordance with the recommendations in the aRMM/CPM</measure>
    <time_frame>18 - 24 months</time_frame>
    <description>Timing and frequency of liver testing conducted by the patients's HCP</description>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Uterine Fibroids</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The survey will endeavor to collect 150 completed patient surveys&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who have received Fibristal within 6 months of completing the survey.&#xD;
&#xD;
          -  Patients who have provided permission to share their responses in aggregate with&#xD;
             Health Canada.&#xD;
&#xD;
          -  Patients who have provided informed consent for their participation in the survey.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who participated in the cognitive pre-testing of the survey questionnaire to&#xD;
             be used for the study.&#xD;
&#xD;
          -  Patients who have been direct employees of Allergan, ICON, Health Canada, or&#xD;
             Professional Targeted Marketing (PTM) within the past year.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahunna Ukah</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Trials Registry Team</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92622</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 1, 2020</study_first_submitted>
  <study_first_submitted_qc>September 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2020</study_first_posted>
  <last_update_submitted>October 21, 2020</last_update_submitted>
  <last_update_submitted_qc>October 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Allergan will share de-identified patient-level data and study-level data including protocols and clinical study reports for phase 2 - 4 trials completed after 2008 that are registered to ClinicalTrials.gov or EudraCT, have received regulatory approval in the United States and/or the European Union in a given indication and the primary manuscript from the trial has been published. To request access to the data, the researcher must sign a data use agreement and any shared data is to be used for non-commercial purposes. More information can be found on http://www.allerganclinicaltrials.com/.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After having received regulatory approval in the United States and/or the European Union in a given indication and the primary manuscript from the trial has been published.</ipd_time_frame>
    <ipd_access_criteria>To request access to the data, the researcher must sign a data use agreement and any shared data is to be used for non-commercial purposes.</ipd_access_criteria>
    <ipd_url>http://www.allerganclinicaltrials.com/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

